Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial Read more about Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial
Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes Read more about Jardiance® meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes
Update on Merck's New Scientific Efforts to Help Combat COVID-19 Read more about Update on Merck's New Scientific Efforts to Help Combat COVID-19
Bayer Extends Clinical Development Program for Finerenone with Phase III Study in Patients with Heart Failure and Preserved Ejection Fraction Read more about Bayer Extends Clinical Development Program for Finerenone with Phase III Study in Patients with Heart Failure and Preserved Ejection Fraction
MyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy Read more about MyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
MyoKardia Launches New HCM Disease Awareness Website Read more about MyoKardia Launches New HCM Disease Awareness Website
FDA Approves New Treatment For a Type of Heart Failure Read more about FDA Approves New Treatment For a Type of Heart Failure
